Literature DB >> 32048741

The progress of 2019 novel coronavirus event in China.

Guan Wang1, Xian Jin2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32048741      PMCID: PMC7166326          DOI: 10.1002/jmv.25705

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


× No keyword cloud information.
It has been more than 1 month since the first 2019‐nCoV infected person was diagnosed. So far, 42 638 people have been diagnosed as 2019‐nCoV pneumonia, which also known as Wuhan pneumonia, among them, 7333 are severe cases, 1016 patients died, and only 3996 patients have been cured in the mainland of China (Hong Kong, Macao, and Taiwan were excluded). All 31 provincial‐level regions and the Xinjiang Production Corps have the confirmed cases. Hubei province, where believed to be the origin of Wuhan pneumonia outbreak, suffers the most, with 31 728 confirmed cases and 974 death cases. The trend of cumulative cases is soaring, including 24 other countries outside of China had confirmed cases. With a remarkable notice that the total number of cases has far exceeded the number during severe acute respiratory syndrome (SARS) period. The first case of 2019‐nCoV pneumonia was linked to wild animal trading in the Huanan seafood market in the city of Wuhan, the capital of Hubei province. Zhou et al found the initial source of 2019‐nCoV probably originated from the Chinese horseshoe bat since the novel coronavirus was 96% identical to a bat coronavirus at a whole genome level. This coronavirus, which has not been identified in humans previously, had been detected from patients in Wuhan and it was the first case for human infection with 2019‐nCoV from wild animals. Recently, Wu et al estimated 75 815 individuals would be infected in Wuhan, with an uncertainty range from 37 304 to 130 330 by using the susceptible‐exposed‐infectious‐recovered model. While the variation of the virus is still under surveillance. Coronaviruses are a huge family of viruses, of which severe acute respiratory syndrome coronavirus (SARSnCoV) and Middle East respiratory syndrome coronavirus (MERS‐nCoV), and so on have already known by humans. The 2019‐nCoV has an incubation period of 3 to 7 days in general, with a maximum of 14 days. The most common symptoms at the onset of illness are fever, cough, and myalgia or fatigue. , While a few patients might have stuffiness, pharyngalgia, or diarrhea. By far, the main sources of infection are 2019‐nCoV infected humans, however, the asymptomatic infection might also be a source of infection. These patients are not easy to be detected among the population when initially infected but might have headache, fever, dyspnea, fatigue, and so on later. This type of coronavirus has been proved could spread from person to person through the respiratory tract and contact transmission. , Zhang et al pointed out the digestive system might also be a potential route of 2019‐nCoV infection based on bioinformatics analysis. Wu et al found R 0, the basic reproduction number is around 2.68 with 2.47 to 2.86 of 95% credible interval, by applied Markov Chain Monte Carlo methods, where transmission characteristics appear to be similar of SARS. Mild and occult cases could be the major concerns for disease prevention. , The World Health Organization (WHO) recommends wearing a medical mask when leaving homes and ethanol and the high temperature had been proved could prevent disease occurrence. The event has been determined as a Public Health Emergency of International Concern by WHO. Humans are generally susceptible to coronavirus. The youngest infected patient is only 1 month after birth. Death cases were mostly found in the elderly and who already have chronic conditions. , The confirmed case is defined as either positive of novel coronavirus nucleic acid by real‐time fluorescent reverse transcription‐polymerase chain reaction detection of respiratory or blood specimens or highly homologous to any known novel coronaviruses through virus gene sequencing of respiratory or blood specimens. Only when body temperature returns to normal for more than 3 days, respiratory symptoms significantly improved and two consecutive tests negative of the nucleic acid of respiratory pathogens, with at least 1 day on sampling interval, people could be allowed to discharge from hospital (Figure 1).
Figure 1

The trend of 2019‐nCoV pneumonia cases

The trend of 2019‐nCoV pneumonia cases The key nodes in 2019‐nCoV pneumonia event The Chinese government has taken emergency measures to support population prevention and clinical treatment after the outbreak and made remarkable progress in responding to disease control comparing with SARS time (Figure 3). , The National Health Commission has set 2019‐nCoV pneumonia as a category B infectious disease with A‐class management on 20 January. Provincial Bureau of health from Shanghai, Anhui, Zhejiang, and so on have organized medical teams, mainly including medical staff from the respiratory department, infections department and critical care medication, hurried to Wuhan for medical support. “Huo Shen Shan” had been established for the centralized treatment of Wuhan pneumonia patients by reference to the model of Xiao Tang Shan hospital in Beijing during the SARS period. Although the cure rate has been rising up, compared with the fast‐growing cases and fatality rate from the updated collected data, it is still required to improve (Table 1). Through the efforts of scientists, Chinese Center for Disease Control and Prevention (CDC) has obtained the full‐length genome of 2019‐nCoV from clinical specimens and found the sequence of the genome has significant differences from any known coronavirus, which is most related to the nucleotide sequence of bat‐SL‐CoVZC45 with 85% sequence similarity. , All the found genome sequence of 2019‐nCoV has been published as open data for scientific research as disease prevention and control. CDC is also conducting the medication screening for Wuhan pneumonia and developing a vaccine for 2019‐nCoV. University of Queensland, GeoVax Labs Inc, and other world‐class research teams have also been joining in the research of vaccine development. , The Ministry of Health Disease Control Bureau also takes psycho crisis intervention and assistance for the population in need. Figure 2 showed the key nodes in the Wuhan pneumonia event, including government measures.
Figure 3

The comparison between 2019‐nCoV and severe acute respiratory syndrome event development

Table 1

The updated cases of 2019‐nCoV pneumonia

DateCumulative casesRegular casesNew casesSevere casesCumulative deathsCumulative curedFatality rateCure rate
1.2029113977446252.062%8.591%
1.214401551491029252.045%5.682%
1.225713031319517252.977%4.378%
1.2383033525917725343.012%4.096%
1.24128752744423741383.186%2.953%
1.25197585868832456492.835%2.481%
1.262744138376946180512.915%1.859%
1.27451516021771976106602.348%1.329%
1.2859743041145912391321032.210%1.724%
1.2977114310173713701701242.205%1.608%
1.3096925799198215272131712.198%1.764%
1.3111 7917392210217952592432.197%2.061%
2.0114 3809048259021103043282.114%2.281%
2.0217 20511 244282922963614752.098%2.761%
2.0320 43813 358323527884256322.079%3.092%
2.0424 32415 836388732194908922.014%3.667%
2.0528 01818 7493694385956311532.009%4.115%
2.0631 16121 0213143482163615402.041%4.942%
2.0734 54622 2743399610172220502.090%5.934%
2.0837 19824 8942656618881126492.180%7.121%
2.0940 17126 4363062648490832812.260%8.168%
2.1042 63827 81524787333101639962.383%9.372%

Note: ; cumulative cases = regular cases + new cases + severe cases + cumulative deaths + cumulative cured.

The above data only represented cases in mainland of China, Hong Kong, Taiwan, and Macau were excluded. Data were collected from National Health Commission of the People's Republic of China. Available from http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml

Figure 2

The key nodes in 2019‐nCoV pneumonia event

The comparison between 2019‐nCoV and severe acute respiratory syndrome event development The updated cases of 2019‐nCoV pneumonia Note: ; cumulative cases = regular cases + new cases + severe cases + cumulative deaths + cumulative cured. The above data only represented cases in mainland of China, Hong Kong, Taiwan, and Macau were excluded. Data were collected from National Health Commission of the People's Republic of China. Available from http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml It has turned out to be urgent for epidemiologists, virologists, biologists, clinical doctors, and pharmaceutical researchers working together to battle against coronavirus outbreak. Human beings should engrave this zoonotic disease in mind for better dealing with “One‐Human‐Environmental‐Animal‐Health.” We believe this novel coronavirus could be wiped out under the joint efforts of scientists around the world soon.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.
  13 in total

1.  Response to the emerging novel coronavirus outbreak.

Authors:  Ilona Kickbusch; Gabriel Leung
Journal:  BMJ       Date:  2020-01-31

2.  China coronavirus: what do we know so far?

Authors:  Elisabeth Mahase
Journal:  BMJ       Date:  2020-01-24

3.  A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment.

Authors:  Vincent J Munster; Marion Koopmans; Neeltje van Doremalen; Debby van Riel; Emmie de Wit
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

4.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

5.  Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China.

Authors:  Weier Wang; Jianming Tang; Fangqiang Wei
Journal:  J Med Virol       Date:  2020-02-12       Impact factor: 2.327

6.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.

Authors:  Jasper Fuk-Woo Chan; Shuofeng Yuan; Kin-Hang Kok; Kelvin Kai-Wang To; Hin Chu; Jin Yang; Fanfan Xing; Jieling Liu; Cyril Chik-Yan Yip; Rosana Wing-Shan Poon; Hoi-Wah Tsoi; Simon Kam-Fai Lo; Kwok-Hung Chan; Vincent Kwok-Man Poon; Wan-Mui Chan; Jonathan Daniel Ip; Jian-Piao Cai; Vincent Chi-Chung Cheng; Honglin Chen; Christopher Kim-Ming Hui; Kwok-Yung Yuen
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

7.  Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study.

Authors:  Joseph T Wu; Kathy Leung; Gabriel M Leung
Journal:  Lancet       Date:  2020-01-31       Impact factor: 79.321

8.  China's response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response.

Authors:  John Nkengasong
Journal:  Nat Med       Date:  2020-03       Impact factor: 53.440

9.  Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020.

Authors:  Julien Riou; Christian L Althaus
Journal:  Euro Surveill       Date:  2020-01

10.  The progress of 2019 novel coronavirus event in China.

Authors:  Guan Wang; Xian Jin
Journal:  J Med Virol       Date:  2020-02-26       Impact factor: 2.327

View more
  28 in total

Review 1.  Coronavirus Disease 2019-COVID-19.

Authors:  Kuldeep Dhama; Sharun Khan; Ruchi Tiwari; Shubhankar Sircar; Sudipta Bhat; Yashpal Singh Malik; Karam Pal Singh; Wanpen Chaicumpa; D Katterine Bonilla-Aldana; Alfonso J Rodriguez-Morales
Journal:  Clin Microbiol Rev       Date:  2020-06-24       Impact factor: 26.132

Review 2.  The COVID-19 pandemic and the potential treatment of the novel coronavirus SARS-CoV-2.

Authors:  Shilei Wang; Jinlei Ye; Zhichao Kang; Hongmei Peng; Vienna Mackey; Lichun Sun
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

3.  Impact of Population Emigration from Wuhan and Medical Support on COVID-19 Infection in China.

Authors:  Yang Yao; Yao Tian; Jing Zhou; Xin Diao; Ligai Di; Shengyu Wang
Journal:  J Epidemiol Glob Health       Date:  2020-12-08

Review 4.  Coronavirus Disease 2019 (COVID-19) in Neonates and Children From China: A Review.

Authors:  Yuanqiang Yu; Pingyang Chen
Journal:  Front Pediatr       Date:  2020-05-15       Impact factor: 3.418

5.  The Difficulties and Mental Health Intervention Need of Doctors and Nurses in Biological Emergencies: A Qualitative Study.

Authors:  Mining Liang; Yamin Li; Qiongni Chen; Haihong Tan; Li He; Caihua Sheng; Yiwen Cai; Xiaojuan Li; Zhanzhou Zhang; Jianjian Wang; Qian Wang; Jincai Guo
Journal:  Front Psychiatry       Date:  2021-06-18       Impact factor: 4.157

6.  COVID-19: Phylogenetic approaches may help in finding resources for natural cure.

Authors:  Wajid Zaman; Saddam Saqib; Fazal Ullah; Asma Ayaz; Jianfei Ye
Journal:  Phytother Res       Date:  2020-07-10       Impact factor: 6.388

Review 7.  [The prevalence rate of anti-SARS-CoV-2-IgG is 1.2% - Screening in asymptomatic outpatients in Germany (Northrhine-Westfalia)].

Authors:  Burkhard L Herrmann
Journal:  MMW Fortschr Med       Date:  2020-08

8.  Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment.

Authors:  Shuntong Kang; Wenyao Peng; Yuhao Zhu; Shiyao Lu; Min Zhou; Wei Lin; Wenfang Wu; Shu Huang; Liping Jiang; Xuan Luo; Meichun Deng
Journal:  Int J Antimicrob Agents       Date:  2020-03-29       Impact factor: 5.283

Review 9.  The epidemiology and clinical information about COVID-19.

Authors:  Huipeng Ge; Xiufen Wang; Xiangning Yuan; Gong Xiao; Chengzhi Wang; Tianci Deng; Qiongjing Yuan; Xiangcheng Xiao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-04-14       Impact factor: 3.267

Review 10.  Comprehensive overview of COVID-19 based on current evidence.

Authors:  Yue Kang; Silu Xu
Journal:  Dermatol Ther       Date:  2020-05-22       Impact factor: 2.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.